Recommendations for Lowering Prescription Drug Spending in Public Programs

2019 ◽  
Vol 171 (11) ◽  
pp. 855
Author(s):  
Shelley A. Jazowski ◽  
Stacie B. Dusetzina
Keyword(s):  
Prescription Drug ◽  
Drug Spending ◽  
Public Programs ◽  
Prescription Drug Spending

scholarly journals Has The Era Of Slow Growth For Prescription Drug Spending Ended?

2016 ◽  
Vol 35 (9) ◽  
pp. 1595-1603 ◽  
Author(s):  
Murray Aitken ◽  
Ernst R. Berndt ◽  
David Cutler ◽  
Michael Kleinrock ◽  
Luca Maini
Keyword(s):  
Prescription Drug ◽  
Slow Growth ◽  
Drug Spending ◽  
Prescription Drug Spending

Prescription Drug Spending Trends For The Privately Insured In Maryland, 2000–2001

2004 ◽  
Vol 23 (5) ◽  
pp. 226-232
Author(s):  
Fadia T. Shaya ◽  
Steven Blume ◽  
C. Daniel Mullins
Keyword(s):  
Prescription Drug ◽  
Drug Spending ◽  
Prescription Drug Spending ◽  
Privately Insured

Introduction

2021 ◽  
pp. 3-13
Author(s):  
Neumann Peter J. ◽  
Cohen Joshua T. ◽  
Ollendorf Daniel A
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drug ◽  
Prescription Drugs ◽  
Health Expenditures ◽  
Drug Spending ◽  
Drug Pricing ◽  
Pricing Policies ◽  
Drug Prices ◽  
Financial Difficulties ◽  
Prescription Drug Spending

The pharmaceutical industry has produced wondrous scientific advances, but the progress has come at a cost. US prescription drug spending has increased faster in most recent years than other categories of health and now comprises roughly one-sixth of total health expenditures. Rising costs strain already stretched public budgets. Increasing patient out-of-pocket spending for deductibles and coinsurance has created financial difficulties for many individuals and their families, particularly among the sickest patients. The dueling trends of scientific breakthroughs and ever-rising spending present enduring challenges. On its own, rising spending would not be so concerning, but evidence suggests that drug prices often do not reflect the benefits they provide. Thus, there is an imperative to measure the value of prescription drugs and incorporate such measures into drug pricing policies.

States’ Control Of Prescription Drug Spending: A Heterogeneous Approach

2005 ◽  
Vol 24 (4) ◽  
pp. 1032-1038 ◽  
Author(s):  
Nancy E. Morden ◽  
Sean D. Sullivan
Keyword(s):  
Prescription Drug ◽  
Drug Spending ◽  
Prescription Drug Spending

scholarly journals National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending

2016 ◽  
Vol 35 (1) ◽  
pp. 150-160 ◽  
Author(s):  
Anne B. Martin ◽  
Micah Hartman ◽  
Joseph Benson ◽  
Aaron Catlin ◽  
Keyword(s):  
Prescription Drug ◽  
National Health ◽  
Health Spending ◽  
Drug Spending ◽  
Prescription Drug Spending ◽  
Coverage Expansion

scholarly journals Demand Effects of Recent Changes in Prescription Drug Promotion

2003 ◽  
Vol 6 (1) ◽  
Author(s):  
Meredith B. Rosenthal ◽  
Ernst R. Berndt ◽  
Julie M. Donohue ◽  
Arnold M. Epstein ◽  
Richard G. Frank
Keyword(s):  
Prescription Drug ◽  
Drug Market ◽  
Drug Spending ◽  
Direct To Consumer ◽  
On Demand ◽  
Therapeutic Class ◽  
Drug Promotion ◽  
Prescription Drug Spending ◽  
Direct To Consumer Advertising ◽  
Prescription Drug Market

The release of clarified Food and Drug Administration (FDA) guidelines and independent changes in consumer behavior provide an opportunity to study the effects of direct-to-consumer advertising (DTCA) in the prescription drug market alongside the effects of various physician-oriented promotions. We examine the effects of DTCA and detailing for brands in five therapeutic classes of drugs, using monthly aggregate U.S. data from August 1996 through December 1999. In terms of impact of DTCA on demand, we provide evidence on two issues: (1) do increases in DTCA increase the market size of an entire therapeutic class? and (2) does DTCA increase within-class market share of advertised drugs? Our findings suggest that, for these classes of drugs, DTCA has been effective primarily through increasing the size of the entire class. Overall, we estimate that 13 to 22 percent of the recent growth in prescription drug spending is attributable to the effects of DTCA.

Sign in / Sign up

Export Citation Format

Share Document